A Nature Medicine review published in January 2026 described GLP-1 medicines as "being prescribed to growing numbers of patients worldwide" for an expanding list of indications and noted that "new, more effective molecules with optimised pharmacokinetics produce greater weight loss and some may be more effective for various metabolic disorders, through incorporation of one or more additional peptide epitopes." The clinical pipeline includes 39 GLP-1 receptor agonist drugs in development across 34 companies, with only seven coming from the top 20 pharmaceutical firms
The SFN extract was found to be highly effective in blocking the activity of inactivation of an oncogenic factor pSTAT3
Only 12 states had any med spa-specific provisions: Connecticut, Iowa, Illinois, Indiana, Massachusetts, New Mexico, Oklahoma, Rhode Island, Tennessee, Texas, Utah, and Wisconsin
The evidence: Clinical interest
This bond signals the pituitary to release growth hormone (GH) into circulation